Congestive heart failure in patients treated with doxorubicin

S. Swain,F. Whaley,M. Ewer
DOI: https://doi.org/10.1002/cncr.11407
IF: 6.9209
2003-06-01
Cancer
Abstract:Doxorubicin is a highly effective and widely used cytotoxic agent with application that is limited by cardiotoxicity related to the cumulative dose of the drug. A large‐scale study that retrospectively evaluated the cardiotoxicity of doxorubicin reported that an estimated 7% of patients developed doxorubicin‐related congestive heart failure (CHF) after a cumulative dose of 550 mg/m2. To assess whether this estimate is reflective of the incidence in the broader clinical oncology setting, the authors evaluated data from three prospective studies to determine both the incidence of doxorubicin‐related CHF and the accumulated dose of doxorubicin at which CHF occurs.
What problem does this paper attempt to address?